Table 1.
Clinicopathological data and PD-L1 expression overall; PD-L1 positive cases on tumor cells and on immune cells.
| Category | PD-L1 positive | PD-L1 negative | IC PD-L1 positive | TC PD-L1 positive | Tot | |
|---|---|---|---|---|---|---|
| Gender, n (%) | Female | 10 (43.5%) | 13 (56.5%) | 8 (34.8%) | 5 (21.7%) | 23 |
| Male | 8 (23.5%) | 26 (76.5%) | 6 (17.6%) | 4 (11.8%) | 34 | |
| Mean age at diagnosis (range) | 67 (41-87) | 66 (44-79) | 67 (41-87) | 67 (43-81) | 57 | |
| Primary tumor, n (%) | GEP | 6 (28.6%) | 15 (71.4%) | 3 (14.3%) | 3 (14.3%) | 21 |
| Lung | 4 (25%) | 12 (75%) | 4 (25%) | 2 (12.5%) | 16 | |
| Other | 8 (40%) | 12(60%) | 7(35%) | 4(20%) | 20 | |
| Genitourinary tract | 3 (37.5%) | 5 (62.5%) | 3 (37.5%) | 0 | 8 | |
| ENT | 2 (50%) | 2 (50%) | 2 (50%) | 2 (50%) | 4 | |
| MCC | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | 1 | |
| CUP | 2 (28.6%) | 5 (71.4%) | 1 (14.3%) | 2 (28.6%) | 7 | |
| Disease extension, n (%) | Locally confined | 2 (25%) | 6 (75%) | 2 (25%) | 1 (12.5%) | 8 |
| Locally advanced | 9 (56.3%) | 7 (43.8%) | 9 (56.3%) | 3 (18.8%) | 16 | |
| Extended | 7 (24.1%) | 22 (75.9%) | 3 (10.3%) | 5 (17.2%) | 29 | |
| Missing data | 4 | |||||
| Histology, n (%) | NET | 0 | 3 (100%) | 0 | 0 | 3 |
| NEC | 17 (35.4%) | 31 (64.6%) | 14 (29.2%) | 8 (16.7%) | 48 | |
| MiNEN | 1 (16.7%) | 5 (83.3%) | 0 | 1 (16.7%) | 6 | |
| Mean Ki-67 index (range) | 80 (40-90) | 70 (21-100) | 80 (40-90) | 80 (40-90) | 52 |
CUP, cancer of unknown primary; ENT, ear-nose-throat; GEP, gastro-entero-pancreatic; IC, immune cells; MCC, Merkel cell carcinoma; MiNEN, mixed neuroendocrine-nonneuroendocrine neoplasm; NEC poorly differentiated neuroendocrine carcinoma; NET, well-differentiated neuroendocrine tumor; PD-L1, programmed cell death ligand 1; TC, tumor cells; Tot, total.